significant parametric pairwise t-test (p£0.05) and ii) area under the receiver-operator characteristic curve (AUROC !0.59) were selected for inclusion in a logistic regression model. Results The biomarkers that met criteria and were taken forward for further analysis are shown in Table 1 . Of these CC16, CRP, MMP8 and NGAL combined had an AUROC 0.82 (95% confidence interval 0.74 to 0.90). The Youden's index gave a sensitivity and specificity of 78% and 82% respectively. Conclusion COPD exacerbations can be identified by urinary biomarkers. The biomarker panel requires further validation in a prospective longitudinal study. Background There is evidence that acute exacerbations of COPD (AECOPD) may be stratified by peripheral blood eosinophil count and that this may allow identification of a pathologically distinct phenotype with clinical value. We have compared lung function measures between patients with eosinophilic and non-eosinophilic AECOPD. Methods All admissions to an inner London teaching hospital with AECOPD were recorded between 2004 and 2012. The eosinophilic phenotype is defined as a first blood count within 24 hours of admission showing peripheral blood eosinophil count ³ 2% of white blood cells. The first lung function test recorded, performed in a dedicated-laboratory between admissions, were used in analysis. We used non-parametric statistics (Mann-Witney U) for univariate comparisons, and linear regression for multivariate analyses.
Background There is evidence that acute exacerbations of COPD (AECOPD) may be stratified by peripheral blood eosinophil count and that this may allow identification of a pathologically distinct phenotype with clinical value. We have compared lung function measures between patients with eosinophilic and non-eosinophilic AECOPD. Methods All admissions to an inner London teaching hospital with AECOPD were recorded between 2004 and 2012. The eosinophilic phenotype is defined as a first blood count within 24 hours of admission showing peripheral blood eosinophil count ³ 2% of white blood cells. The first lung function test recorded, performed in a dedicated-laboratory between admissions, were used in analysis. We used non-parametric statistics (Mann-Witney U) for univariate comparisons, and linear regression for multivariate analyses.
Results There were 2793 admissions with AECOPD recorded, we used only first admissions (1, 279 Abstract P186 Figure 1 Discussion In this cohort, patients admitted to hospital with acute exacerbations of COPD associated with an eosinophilic phenotype had a higher FEV1 and higher DLCO% predicted. A lower DLCO is more associated with an "emphysematous" than "bronchial" form of COPD. Our Results suggest that the eosinophilic phenotype of AECOPD may be associated with less alveolar and pulmonary capillary damage. Background Patients presenting with an acute exacerbation of COPD (AECOPD) and a peripheral blood eosinophil count!=2% of the total white cell count have a better response to oral cortico-steroids, suggesting that stratification by this biomarker identifies a pathologically distinct phenotype and has clinical value. 1 We have tested the hypothesis that the eosinophilic and non-eosinophilic exacerbations of COPD have different seasonality using a dataset of patents admitted to an inner London teaching hospital with AECOPD over 9 years. Methods All admissions with AECOPD were recorded between 2004 and 2012. We recorded the first blood test result within 24 hours of admission. The month of admission was recorded. Seasons were defined as per figure 1 and the distribution of eosinophilic (blood eosinophil count=2%) and non-eosinophilic events compared. Results 2793 admissions with AECOPD were recorded, of which 2416 (86.5%) had a FBC result available and 750 (31.0%) were eosinophilic. The mean age of the entire population was 70 with 44.3% female. Eosinophilic admissions had a median age 69.3 of which 40.5% were female. Non-eosinophilic admissions had a median age 70.9 of which 46.9% were female. There were no significant differences between the number of eosinophilic exacerbations across seasons. In contrast, non-eosinophilic exacerbations occurred more commonly in winter compared to summer. The proportion of eosinophilic events was 36.5 vs 28.1% in summer and winter respectively (mean difference 9%; 95% CI 4%-14%; p=0.003). Introduction Chronic Obstructive Pulmonary Disease (COPD) patients experience dyspnoea and cough and are prone to episodes of rapid worsening, termed acute exacerbations (AECOPD). Infections, air pollution and gastroesophageal reflux (GOR) have all been implicated in AECOPD.
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1 Identification of GOR during AECOPD may allow targeted treatment. However, confirmation of GOR requires invasive procedures (e.g., pH manometry). Salivary pepsin measurement using Peptest (RDBiomed Ltd) offers a non-invasive alternative. We investigated the feasibility of using Peptest to detect salivary pepsin as a biomarker in AECOPD. Methods 30 consecutive patients admitted within the last 24 hours with AECOPD were recruited and saliva collected daily for 7 days using a standard method. Pepsin was measured using Peptest. GOR was considered present if pepsin was 75 ng/ml. Participants completed the following questionnaires on day 1: Frequency Scale for Symptoms of GORD, Hull Airways Reflux Questionnaire and COPD assessment test. Additional demographic and clinical data were collected. Data are presented as mean ±SD. Results Thirty patients (Males: 18, Age: 64.1±12.6, current smokers: 18) were recruited over 30 days. 81% of eligible patients consented. 70% completed the study. Salivary pepsin levels over 7 days are presented in figure 1. 24/30 participants (80%) had salivary pepsin 75 ng/ml on day 1. Mean pepsin levels reduced significantly during the 7 days with highest levels observed on day 1 (p<0.01). There was no correlation Abstract P187 Figure 1 between day 1 salivary pepsin and symptom questionnaires. Salivary pepsin measurement over 7 days identified four patterns: persistently low (n=3); persistently high (n=3); high on day 1 only (n=6); and variable (n=13). Discussion Peptest was acceptable to patients. Salivary pepsin measurement appears to be able to categorise different population groups by pattern of pepsin concentration throughout the week. As a feasibility study, it was not powered to identify correlation with clinical outcomes. Our Results suggest that using salivary pepsin as a marker of GOR is feasible and is worthy of further study in a large prospective cohort to evaluate its relationship to outcomes.
Introduction and Objectives COPD patients with acute exacerbations make up a significant proportion of the inpatient hospital population. This patient group is at risk of recurrent readmission to hospital, which not only reduces patient quality of life but also has financial implications. The aim of this study was to correctly identify COPD patients at high risk of readmission and reduce this by addressing reversible factors and/or creating an anticipatory care plan (ACP). Methods 200 consecutive admissions with an acute exacerbation of COPD were reviewed to identify risk factors for readmission at 28 days or mortality within 6 months. Patients who were identified as high risk of readmission were reviewed using an algorithm to identify potential reversible factors and if ACP would be appropriate. This review was carried out either during admission or at the point of discharge. Results The following factors were shown to predict readmission or death, recurrent admissions (2 in the last year) (readmission: p=0.002, OR=3.56, death: p=«0.001, OR=11.64), NIV during admission (readmission: p=0.073, OR=4.06, death: p=0.023, OR=7.17) and long term oxygen therapy (readmission: p=0.034, OR=3.23, death: p=«0.001, OR=9.22). 72 subjects were identified as having a high risk of readmission. Of these 72 subjects, 14 had the algorithm applied during admission (prospectively) and 58 at the point of discharge (retrospectively). 53% of the study population was readmitted within 28 days. 21% of the prospective group was readmitted compared to 60% of the retrospective group. 55% of the prospective group had an ACP in place compared to 32% of the retrospective group. Conclusions By identifying characteristics associated with high risk of readmission in patients with COPD, we were able to apply an algorithm in the hope of reducing readmission. Although current numbers are small, initial Results indicate that the use of the algorithm during a hospital admission could significantly reduce readmission to hospital. Undoubtedly more data is required. In the future routine use of this proactive approach could potentially improve patient care as well as reduce the financial burden for healthcare providers.
